Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease (opens in a new tab)

medicalxpress.com · 2026-10-24

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. One other point was not covered by the paper.

  • 2 supported
  • 1 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease

medicalxpress.com · 2026-10-24

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Mixed

One claim overstates the study. Two of four check out. One claim the study doesn't address.

  • 2 supported
  • 1 overstated
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4OverstatedThe corresponding author said very elderly people have historically been underrepresented in or excluded from large randomized controlled trials, and that real-world data help address this gap; he also said the oldest and most vulnerable CKD patients can derive substantial benefits but require careful individualized risk-benefit assessment and close monitoring.View evidenceHide evidence

Why this verdict

Partly supported but overstated. The profile supports that very elderly adults were underrepresented in prior SGLT2 inhibitor trials and that this study used real-world EHR data to address that evidence gap. However, the statement that the oldest and most vulnerable CKD patients “can derive substantial benefits” presents a stronger clinical/causal interpretation than the abstract-level observational, propensity-matched evidence can establish. The need for individualized risk-benefit assessment is consistent with the reported safety signals, but the exact author quote and close-monitoring language are not directly verifiable in the supplied abstract profile.

1

Study evidence

SGLT2i initiation was associated with lower all-cause mortality compared with non-use in propensity-score matched adults ≥80 years with CKD.aHR 0.818 (95% CI 0.746–0.896), p<0.0001

“This retrospective cohort study used data from TriNetX Research Network, a multicenter electronic health record database.”
2

Study evidence

No significant difference in major adverse cardiovascular events (MACE) between SGLT2i initiators and non-initiators.aHR 1.007 (95% CI 0.938–1.082; p=0.84)

“major adverse cardiovascular events (MACE)”
Claim 2 of 4Not coveredNew research suggests potential benefits and risks of SGLT2 inhibitors for adults aged 80 years or older with chronic kidney disease, and the findings will be presented at ASN Kidney Week 2026.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the scientific framing that SGLT2 inhibitor initiation in adults aged ≥80 years with CKD was associated with both potential benefits and safety risks in a real-world EHR cohort. However, the supplied paper profile does not verify the ASN Kidney Week 2026 presentation venue/date, so that component is not verifiable from the provided abstract-depth evidence.

1

Study evidence

SGLT2i initiation was associated with lower all-cause mortality compared with non-use in propensity-score matched adults ≥80 years with CKD.aHR 0.818 (95% CI 0.746–0.896), p<0.0001

“This retrospective cohort study used data from TriNetX Research Network, a multicenter electronic health record database.”
2

Study evidence

No significant difference in major adverse cardiovascular events (MACE) between SGLT2i initiators and non-initiators.aHR 1.007 (95% CI 0.938–1.082; p=0.84)

“major adverse cardiovascular events (MACE)”
Claim 3 of 4SupportedIn an analysis of electronic health records data on 10,076 adults aged 80 years or older with CKD, initiating SGLT2 inhibitor therapy was linked to an 18% reduction in all-cause mortality and a 22% reduction in major adverse kidney events over two years.View evidenceHide evidence

As stated18% reduction in all-cause mortality; 22% reduction in major adverse kidney events

Why this verdict

Supported. The profile reports a TriNetX EHR retrospective cohort with 5,038 matched SGLT2i initiators and 5,038 matched non-users, totaling 10,076 adults aged ≥80 with CKD. It reports lower all-cause mortality, aHR 0.818, and fewer major adverse kidney events, aHR 0.779, over approximately two years, corresponding closely to the story’s 18% and 22% relative reductions. The story frames this as linked/associated, which matches the observational evidence.

1

Study evidence

SGLT2i initiation was associated with lower all-cause mortality compared with non-use in propensity-score matched adults ≥80 years with CKD.aHR 0.818 (95% CI 0.746–0.896), p<0.0001

“This retrospective cohort study used data from TriNetX Research Network, a multicenter electronic health record database.”
Claim 4 of 4SupportedThe treatment was not associated with a significant overall effect on major adverse cardiovascular events, but it was associated with higher risks of specific cardiac events such as heart attacks and acute heart failure, as well as acute kidney injury.View evidenceHide evidence

Why this verdict

Supported. The profile reports no significant difference in MACE, aHR 1.007 with p=0.84, while also reporting higher AKI risk and increases in acute myocardial infarction and acute heart failure in the SGLT2i group. The story does not state numerical magnitudes for these safety/component outcomes, which is appropriate because the abstract-level profile does not provide them.

1

Study evidence

SGLT2i initiation was associated with lower all-cause mortality compared with non-use in propensity-score matched adults ≥80 years with CKD.aHR 0.818 (95% CI 0.746–0.896), p<0.0001

“This retrospective cohort study used data from TriNetX Research Network, a multicenter electronic health record database.”
2

Study evidence

No significant difference in major adverse cardiovascular events (MACE) between SGLT2i initiators and non-initiators.aHR 1.007 (95% CI 0.938–1.082; p=0.84)

“major adverse cardiovascular events (MACE)”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Important limitation: the abstract does not provide numerical effect estimates, confidence intervals, absolute event rates, or detailed outcome ascertainment methods for AKI, AMI, and acute heart failure.

    The story reports increased risks for these safety/component outcomes but does not note that the abstract-level evidence lacks magnitude estimates and ascertainment details, which affects how strongly those safety signals can be interpreted.

    From Retrospective EHR cohort with propensity-score matching and Cox proportional hazards time-to-event analysis

6 things the story did carry across
  • The study was a retrospective, observational TriNetX multicenter EHR cohort using propensity-score matching, not a randomized trial.
  • Matched cohort size and population: 5,038 SGLT2i initiators and 5,038 non-users, totaling 10,076 adults aged ≥80 years with CKD.
  • Primary benefit findings: SGLT2i initiation was associated with lower all-cause mortality and fewer major adverse kidney events over approximately two years.
  • Cardiovascular composite finding: no significant overall difference in major adverse cardiovascular events.
  • Safety/component signals: higher AKI risk and increased acute myocardial infarction and acute heart failure were reported in the SGLT2i group.
  • Important limitation: residual confounding remains possible despite propensity-score matching because the study is observational EHR research.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataAssess whether initiation of SGLT2 inhibitors (vs non-use) is associated with lower all-cause mortality and improved kidney outcomes (MAKE and related renal endpoints) in adults aged ≥80 years with chronic kidney disease using real-world EHR data.Retrospective EHR cohort with propensity-score matchingExpand

In plain English

Retrospective, propensity score–matched cohort study of adults aged ≥80 years with chronic kidney disease in the TriNetX multicenter EHR network (index events 2021-01-01 to 2025-01-01). Among 5,038 matched SGLT2i initiators and 5,038 matched non-users followed for up to two years, initiation of SGLT2 inhibitors was associated with lower all-cause mortality and fewer major adverse kidney events (MAKE) but no difference in major adverse cardiovascular events (MACE). Certain safety signals were reported (higher acute kidney injury, increased acute myocardial infarction and acute heart failure), while incident dialysis and end-stage renal disease were reduced. Analyses used propensity score matching to balance baseline covariates and Cox proportional hazards models to estimate adjusted hazard ratios.

Key findings

  • SGLT2i initiation was associated with lower all-cause mortality compared with non-use in propensity-score matched adults ≥80 years with CKD.aHR 0.818 (95% CI 0.746–0.896), p<0.0001
  • SGLT2i initiation was associated with fewer major adverse kidney events (MAKE).aHR 0.779 (95% CI 0.715–0.850), p<0.0001
“This retrospective cohort study used data from TriNetX Research Network, a multicenter electronic health record database.”
What this piece can’t prove
  • Retrospective observational design using EHR data; despite propensity score matching, residual confounding is possible.

3 further details could not be confirmed from the summary.

2secondary dataAssess whether SGLT2 inhibitor initiation is associated with cardiovascular outcomes (MACE and component cardiac events) and safety signals (e.g., AKI) in the same very-elderly CKD cohort.Retrospective EHR cohort with propensity-score matching and Cox proportional hazards time-to-event analysisExpand

In plain English

In a TriNetX-derived, propensity-score matched retrospective cohort of adults ≥80 years with CKD (5,038 SGLT2i initiators vs 5,038 non-initiators, 2-year follow-up), SGLT2i initiation was not associated with a difference in MACE but was reported to have higher risk of acute kidney injury and increased rates of acute myocardial infarction and acute heart failure (effect estimates for these safety/component events not provided in the abstract).

Key findings

  • No significant difference in major adverse cardiovascular events (MACE) between SGLT2i initiators and non-initiators.aHR 1.007 (95% CI 0.938–1.082; p=0.84)
  • Risk of acute kidney injury (AKI) was reported to be higher in the SGLT2i group.
“major adverse cardiovascular events (MACE)”
What this piece can’t prove
  • Retrospective EHR data are subject to residual confounding and potential misclassification despite propensity-score matching.
  • Multiplicity of tested outcomes and subgroup analyses not detailed; potential for type I error in reporting increased component events.

1 further detail could not be confirmed from the summary.

3secondary dataEvaluate whether observed associations are consistent across prespecified/clinically relevant subgroups within the matched cohort.Subgroup/stratified analyses within propensity-score matched retrospective EHR cohortExpand

In plain English

The abstract reports that subgroup/stratified analyses were performed within the propensity-score matched TriNetX cohort and that overall results were "generally consistent across subgroups." The abstract provides no subgroup-specific effect estimates, confidence intervals, list of subgroups, or information about prespecification or multiple-comparison adjustment.

Key findings

  • "Results were generally consistent across subgroups." (abstract statement; no subgroup-specific estimates reported)
“Results were generally consistent across subgroups.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

CandidateOpen access

Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases.

Hematology Reports · 2023 · PubMed, Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Review for "SGLT2 Inhibitors and Mortality in Older Adults with Diabetic Kidney Disease: A Target Trial Emulation Study"

2025 · Crossref

Source (opens in a new tab)
Candidate

Review for "SGLT2 Inhibitors and Mortality in Older Adults with Diabetic Kidney Disease: A Target Trial Emulation Study"

2026 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.